文献速递眼底病与葡萄膜炎

玻璃体腔注射甲氨蝶呤治疗和预防增生性玻璃体视网膜病变

INTRAVITREAL METHOTREXATE INJECTION FOR THE TREATMENT AND PREVENTION OF PROLIFERATIVE VITREORETINOPATHY.
PubMed 文献 · Retina · 2024-01-01

回顾性连续病例系列纳入21例(21眼)伴有增生性玻璃体视网膜病变的视网膜脱离或开放眼球伤患者,在玻璃体切除等手术后系列玻璃体腔注射甲氨蝶呤(400 μg/0.1 mL),平均注射10.5次,单次手术视网膜复位19眼(90%),7眼(33%)出现角膜上皮缺损。

要点

  • 21眼中19眼(90%)经单次手术成功复位视网膜。
  • 术后平均接受10.5次玻璃体腔甲氨蝶呤注射(400 μg/0.1 mL)。
  • 7眼(33%)出现角膜上皮缺损。

核心结论

  • 系列玻璃体腔注射甲氨蝶呤与视网膜脱离伴增生性玻璃体视网膜病变或高风险患者90%的单次手术视网膜复位率相关。

研究设计与样本

  • 回顾性病历回顾,连续纳入2021年12月至2024年1月接受系列玻璃体腔甲氨蝶呤注射治疗和/或预防增生性玻璃体视网膜病变的21例患者21眼。

主要发现

  • 21眼均行平坦部玻璃体切除、膜剥离、激光光凝、硅油填充及玻璃体腔甲氨蝶呤注射。
  • 术后所有眼接受玻璃体腔甲氨蝶呤400 μg/0.1 mL注射,理想方案为每周1次共8周、之后每2周1次共4周、总计13次,自视网膜复位手术结束时术中开始。
  • 21例患者平均接受10.5次注射。
  • 术前平均logMAR视力3.2(约手动),术后平均logMAR视力2.5(介于数指与手动之间),平均改善0.7 logMAR单位(0 ETDRS行/字母)。
  • 单次手术视网膜复位19眼(90%),角膜上皮缺损7眼(33%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report on our experience using intravitreal methotrexate (MTX) in patients with retinal detachment associated with proliferative vitreoretinopathy and/or open globe injury. METHODS: This study performed a retrospective chart review of a consecutive series of 21 eyes of 21 patients who underwent serial intravitreal MTX injection for treatment and/or prevention of proliferative vitreoretinopathy from December 2021 to January 2024. RESULTS: Twenty-one patients underwent pars plana vitrectomy, membrane peeling, laser photocoagulation, silicone oil infusion, and intravitreal MTX injection. Postoperatively, all eyes received a series of intravitreal MTX (400 μg/0.1 mL) injections. Optimally, injections were administered weekly for 8 weeks and every 2 weeks for four weeks for a total of 13 injections, beginning intraoperatively at the conclusion of retinal reattachment surgery. Mean baseline preoperative and postoperative visual acuity was logarithm of the minimum angle of resolution 3.2 (approximately hand motions vision) and 2.5 (between CF and hand motions vision), respectively, yielding an average improvement in visual acuity of 0.7 logarithm of the minimum angle of resolution units (0 ETDRS lines/letters). These 21 patients received an average of 10.5 injections. With a single operation, detachments in 19 (90%) of 21 eyes were successfully reattached. Corneal epithelial defects were noted in 7 (33%) of 21 patients. CONCLUSION: Serial intravitreal MTX injection was associated with 90% single operation retinal reattachment rate in the setting of retinal detachment with proliferative vitreoretinopathy or retinal detachment at high risk of proliferative vitreoretinopathy.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Hughes PJ, Bhagat N, Gonzalez-Martinez OG, et al. INTRAVITREAL METHOTREXATE INJECTION FOR THE TREATMENT AND PREVENTION OF PROLIFERATIVE VITREORETINOPATHY. Retina. 2024. PMID: 39287537. doi:10.1097/IAE.0000000000004181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。